^
    1d
    Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov)
    P3, N=132, Recruiting, Ono Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • temozolomide • Velexbru (tirabrutinib)
    2d
    BRAWM: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Sunnybrook Health Sciences Centre | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine
    3d
    REMODEL-2: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov)
    P3, N=1011, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rhapsido (remibrutinib)
    3d
    REMODEL-1: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov)
    P3, N=1001, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rhapsido (remibrutinib)
    4d
    Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=93, Completed, Memorial Sloan Kettering Cancer Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Matulane (procarbazine hydrochloride)
    4d
    Perioperative Management of Targeted and Immunologic Agents in Neurosurgical Oncology. (PubMed, Neurosurgery)
    Modern systemic therapies necessitate refinement of perioperative management in neurosurgical oncology. This review synthesizes data into a pragmatic framework for drug timing and risk mitigation. Considering interruption intervals is essential to balance surgical safety with oncologic control. Integrating these principles can reduce complications, standardize care, and improve outcomes for this complex patient population.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6)
    |
    Imbruvica (ibrutinib)
    5d
    A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=394, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P3 trial
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib) • rocbrutinib (LP-168)
    5d
    POTENTIAL-M: NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, NOBO Medicine | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    poseltinib (HM71224)
    5d
    Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial (clinicaltrials.gov)
    P1/2, N=27, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A deletion
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    5d
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Patrick C. Johnson, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    6d
    Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study (ChiCTR2500115104)
    P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)